scholarly journals ASO Author Reflections: The Association Between Low-Risk DCIS and Screening Ultrasound over the Past 10 Years

2021 ◽  
Author(s):  
Si Eun Lee ◽  
Hee Jung Moon
Keyword(s):  
Low Risk ◽  
The Past ◽  
Screening Ultrasound

The Application of Fundamental Analysis and Technical Analysis in the Athens Derivatives Exchange (ADEX)

2007 ◽  
Vol 8 (1) ◽  
pp. 89-104
Author(s):  
Nikolaos Pavlou ◽  
George Blanas ◽  
Pavlos Golemis
Keyword(s):  
Strong Correlation ◽  
Financial Analysis ◽  
Technical Analysis ◽  
Financial Statements ◽  
Low Risk ◽  
Financial Ratios ◽  
Fundamental Analysis ◽  
Stock Performance ◽  
The Past ◽  
Index Size

Derivatives Market in Greece is under development and investors have a clear lack of advising upon this market. Analysts may say that derivatives have low risk, however investing on them does not always return profits. That is why financial analysis is useful, to inform investors. In this paper we try to apply a financial analysis on derivatives market through two different approaches. The fundamental analysis (FA) investigates a firm’s performance through its financial statements and the technical analysis (TA) takes into consideration the past closing prices of the security. The FA will be set through five different kinds of financial ratios for the last five years and TA through five technical indicators for the last three years. Evaluating the results of each method, we try to find whether there is relation with their sector, index, size, establishment date and import date to ASE or not. Our findings show that in both methods there is no strong correlation between the performance and the five different factors, so stock performance is depending on preferences of the investors and not on the directive factors.

scholarly journals Socioeconomic Status and Intimate Relationships

2021 ◽  
Vol 72 (1) ◽  
pp. 391-414
Author(s):  
Benjamin R. Karney
Keyword(s):  
Socioeconomic Status ◽  
Intimate Relationships ◽  
Mating Strategies ◽  
Low Risk ◽  
Relationship Maintenance ◽  
The Past ◽  
Socioeconomic Context ◽  
Socioeconomic Diversity

The ways that couples form and manage their intimate relationships at higher and lower levels of socioeconomic status (SES) have been diverging steadily over the past several decades. At higher SES levels, couples postpone marriage and childbirth to invest in education and careers, but they eventually marry at high rates and have relatively low risk for divorce. At lower SES levels, couples are more likely to cohabit and give birth prior to marriage and less likely to marry at all. This review examines how SES comes to be associated with the formation, development, and dissolution of intimate relationships. Overall, research has highlighted how a couple's socioeconomic context facilitates some choices and constrains others, resulting in different capacities for relationship maintenance and different adaptive mating strategies for more and less advantaged couples. A generalizable relationship science requires research that acknowledges these differences and one that recruits, describes, and attends to socioeconomic diversity across couples.

The Future Of Master Limited Partnerships

2014 ◽  
Vol 30 (5) ◽  
pp. 1492
Author(s):  
Charles F. Beauchamp
Keyword(s):  
Institutional Investors ◽  
Economic Importance ◽  
Low Risk ◽  
The Past ◽  
Size Number ◽  
The Future ◽  
New Entrants ◽  
Investment Portfolios ◽  
Limited Partnerships ◽  
Business Structure

<p>Master limited partnerships have grown in size, number, and economic importance over the past fifteen years. They now represent a stable and healthy component of many investment portfolios. MLPs have generated impressive risk-adjusted performance compared to that of other equity investments. This performance is the result of their fee-based, low risk business structure that produces a steady cash distribution to investors. The future to these traditional MLPs and similar new entrants is quite positive. However, new entrants that potentially deviate from this successful operating structure are entering the MLP market. This raises major questions regarding the sustainability of these firms as MLPs. This study examines the future of MLP markets within the context of traditional and non-traditional new entrants. Furthermore, the emergence of institutional investors on MLP markets is discussed.</p>

Discriminating Characteristics of Community-Dwelling Elderly at High and Low Risk for Frailty

2002 ◽  
Vol 10 (4) ◽  
pp. 413-431 ◽  
Author(s):  
Laura S. Ho ◽  
Harriet G. Williams ◽  
Emily A.W. Hardwick
Keyword(s):  
Physical Activity ◽  
Regression Analysis ◽  
High Risk ◽  
Daily Living ◽  
Cardiac Event ◽  
Community Dwelling ◽  
Low Risk ◽  
Functional Abilities ◽  
The Past ◽  
And Performance

The study’s objective was to examine the health status, physical activity behaviors, and performance-based functional abilities of individuals classified as being at high or low risk for frailty and to determine which of these characteristics discriminates between the 2 groups. Participants were 78 community-dwelling individuals with an average age of 74 years; 37 were categorized as being at high risk and 42 at low risk for frailty. Logistic-regression analysis indicated that individuals classified as being at high risk for frailty were more likely to have visited the doctor more than 3 times in the past year, experienced a cardiac event, taken more than 4 medications a day, and participated in little or no physical activity. High-risk individuals were more likely to have poor balance, difficulty with mobility, decreased range of motion, poor unimanual dexterity, and difficulty performing activities of daily living than were those classified as being at low risk for frailty.

The Febrile Infant

PEDIATRICS ◽  
1994 ◽  
Vol 94 (3) ◽  
pp. 397-399 ◽  
Author(s):  
Paul L. McCarthy
Keyword(s):  
Negative Predictive Value ◽  
Predictive Value ◽  
Current Issue ◽  
Low Risk ◽  
Serious Illness ◽  
The Past ◽  
Risk Criteria ◽  
Febrile Infant ◽  
Diagnostic Certainty ◽  
Rule Out

There have now been three large prospective studies of febrile infants published within the past 3 years.1-3 Each reports on over 500 patients. Two of the reports, that of Baskin et al1 and that of Jaskiewicz et al,3 in the current issue of Pediatrics, focus on infants meeting low-risk criteria for serious bacterial illness. These two studies ask the question: "If the febrile infant meets these selected low-risk criteria, then with what degree of diagnostic certainty can the examining physician rule out a serious illness?" Statistically, this index of diagnostic certainty is termed negative predictive value. Jaskiewicz et al studied 511 low-risk febrile infants and used 437 of these patients to calculate negative predictive value, which was 98.9%.

scholarly journals Iatrogenic Delayed Pneumothorax After Transbronchial Biopsy

2020 ◽  
Vol 8 ◽  
pp. 232470962094763
Author(s):  
Kartikeya Rajdev ◽  
Dustin N. Herring ◽  
Shubham Lahan ◽  
Kyle Wilson ◽  
Peter J. Murphy
Keyword(s):  
Immunocompromised Patient ◽  
Risk Profile ◽  
Interesting Case ◽  
Transbronchial Biopsy ◽  
Low Risk ◽  
Everyday Practice ◽  
Immunocompromised Patients ◽  
The Past ◽  
Delayed Pneumothorax

Transbronchial biopsy (TBB) is one of the commonly performed procedures by pulmonologists in everyday practice. Although the procedure has a very low-risk profile, complications often develop in certain patients. Pneumothorax is one such complication pertaining to TBB. As only a small percent of procedures get complicated by pneumothorax, handful of cases have been reported with its delayed occurrence in the past 5 decades. The purpose of our report is to highlight another uncommon yet interesting case of delayed iatrogenic pneumothorax in an immunocompromised patient after TBB. Although the chain of events behind the pathophysiology of delayed pneumothorax largely remain a mystery, its development has been linked to altered immune mechanics as they are frequently recognized in immunocompromised patients.

scholarly journals Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1842-1842
Author(s):  
Marie Sebert ◽  
Cendrine Chaffaut ◽  
Sylvain Thepot ◽  
Corentin Orvain ◽  
Thomas Cluzeau ◽  
...  
Keyword(s):  
High Risk ◽  
Lower Risk ◽  
Research Funding ◽  
Low Risk ◽  
Donor Group ◽  
Hematopoietic Stem ◽  
The Past ◽  
Group A ◽  
Group B

Abstract Background: Allo HSCT is a potentially curative treatment in MDS which, in higher risk (IPSS high and int 2) MDS demonstrated an overall survival (OS) advantage over conventional treatment (especially HMAs) in retrospective (Koreth et al., JCO 2013) and prospective (Robin et al. leukemia 2015) studies. Retrospective studies, on the other hand, suggested no OS advantage for allo HSCT in lower risk MDS (IPSS low and int 1), except possibly in the "poorest" lower risk MDS subsets, as classified by the WPSS (Alessandrino et al. AMJH 2013) However, about 25% of lower risk MDS patients are reclassified as higher risk by the R-IPSS and a proportion of other lower risk MDS can also harbor some higher risk features that compromise their outcome. MDS-ALLO-RISK trial (clinicaltrial.gov NCT02757989), was designed to assess outcome of lower risk MDS patients with some high-risk features after HLA-matched donor HSCT. Method: The primary objective of this study was to demonstrate an OS improvement in lower risk MDS patients with some high risk features with a donor compared with those without a donor (with a 3 year OS of 70% versus 40%, respectively) . Inclusion criteria were: IPSS low or int1 MDS with at least one of the following characteristics: 1) R-IPSS intermediate or higher 2) RBC transfusion dependent anemia and failure to two or more treatments (including EPO, Lenalidomide or HMA ); 3) platelets &lt; 20 G/L requiring transfusions 4) ANC &lt; 0.5 G/L with severe infection 5) no contra indication to allo HSCT 6) age &lt;70 years 7) HLA identical donor (sibling or 10/10 unrelated) 105 inclusions were planned: 62 in group with a donor (group A) and 43 in group without a donor (group B). Recruitment began in June 2016 and stopped in March 2021 due to futility on the interim analysis. Median follow-up was 20 months. Data cut off analysis was June 2021. Results: 79 patients were included, 64 in group A and 15 in group B. Median age was 62.4 (IQR: 58-65) years in group A and 66 (IQR: 60.5-68) years in group B. Patients in group A were more frequently males (73 vs 40%, p=0.029), WHO was CMML in 8 (10%), MDS-SLD in 5 (8%), MDS-MLD in 9 (11%), MDS-EB1 in 41 (52%), MDS-RS in 12 (15%), unclassified in 4 (6%) without significant differences between the two groups. IPSS /IPSS-R was similar in both groups: IPSS low in 10% (11% in group A and 7% in group B) and Int-1 in 90%. IPSS-R: very low risk (6% vs 0%); low risk (25% vs 27%); intermediate (50% vs 47%); high (19% vs 27%); no very high risk. Among the 64 patients with a donor, 58 (92%) received HSCT, 2 died before HSCT; 2 had progressive disease and 2 are planned for HSCT. Transplanted patients received reduced intensity conditioning regimen with busulfan 6.4mg/kg, fludarabine 150mg/m2 and ATG (rabbit antithymocyte globulin therapy, grafalon®) 30mg/kg and cyclosporine-mycophenolate mofetil as GVHD prophylaxis. In group A, 21/64 had died, including 13 died from a non-relapse cause. In group B, 4/15 patients had died, 3 from MDS progression and one from CNS bleeding. Three-year OS was 60% (95%CI: 46.9-76.8) in group A and 64.2% (41.3-99.6) in group B (p=NS). At the time of analysis, 20 and 5 patients had progressed/relapsed in group A and B respectively. with a cumulative incidence of relapse/progression (from inclusion) of 27.4% (IC95%: 15;39.8) in group A and 41.7% (IC95%:9.2;74.2) in group B (p=0.71). Among the 58 transplanted patients, 11 (19%) died without disease progression, including one death from a solid tumor. 3 years non-relapse mortality in transplanted patients was 23.4% (IC95%:9.7;37). 3 years Incidence of grade 2 to 4 acute GVHD was 40.8% and 3 years chronic GVHD was 24.9%. Conclusion: In this, to our knowledge, first prospective study in IPSS lower risk patients with some unfavorable clinical or biological features, HLA identical donor (sibling or 10/10 unrelated) HSCT yielded a 3-year OS of 60%. Non relapse mortality was however 23%, and OS somewhat lower than expected (70% at 3 years) and similar to that observed in patients without a donor. Long-term follow-up is needed to better define subgroups of IPSS lower risk MDS that may benefit from allo HSCT. Disclosures Sebert: Abbvie: Consultancy; BMS: Consultancy. Cluzeau: Pfizer: Other: travel, accommodations, expenses; Astellas: Speakers Bureau; Amgen: Speakers Bureau; Agios: Honoraria; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel, accommodations, expenses, Speakers Bureau; Roche: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria, Speakers Bureau; Takeda: Other: travel, accommodations, expenses; Jazz Pharma: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Speakers Bureau. Loschi: AbbVie: Ended employment in the past 24 months, Honoraria; CELGENE/BMS: Honoraria; Gilead: Ended employment in the past 24 months, Honoraria; Novartis: Ended employment in the past 24 months, Honoraria; Servier: Ended employment in the past 24 months, Honoraria; MSD: Honoraria. Huynh: Jazz Pharmaceuticals: Honoraria. Ades: ABBVIE: Honoraria; NOVARTIS: Honoraria; CELGENE/BMS: Honoraria; CELGENE: Research Funding; JAZZ: Honoraria, Research Funding; TAKEDA: Honoraria. Fenaux: JAZZ: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Celgene/BMS: Honoraria, Research Funding; Syros Pharmaceuticals: Honoraria. Robin: NEOVII MEDAC NOVARTIS: Research Funding.

scholarly journals Perceived Versus Actual Risks of 30-Day Readmission in Patients With Cardiovascular Disease

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Hanzhang Xu ◽  
Heather R. Farmer ◽  
Bradi B. Granger ◽  
Kevin L. Thomas ◽  
Eric D. Peterson ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
High Risk ◽  
Perceived Risk ◽  
Odds Ratio ◽  
The United States ◽  
Low Risk ◽  
Health Records ◽  
Factors Associated ◽  
The Past ◽  
Heart Center

Background: Cardiovascular disease (CVD) is the leading cause of hospitalization in the United States, and patients with CVD are at a high risk of readmission after discharge. We examined whether patients’ perceived risk of readmission at discharge was associated with actual 30-day readmissions in patients hospitalized with CVD. Methods: We recruited 730 patients from the Duke Heart Center who were admitted for treatment of CVD between January 1, 2015, and August 31, 2017. A standardized survey was linked with electronic health records to ascertain patients’ perceived risk of readmission, and other sociodemographic, psychosocial, behavioral, and clinical data before discharge. All-cause readmission within 30 days after discharge was examined. Results: Nearly 1-in-3 patients perceived a high risk of readmission at index admission and those who perceived a high risk had significantly more readmissions within 30 days than patients who perceived low risks of readmission (23.6% versus 15.8%, P =0.016). Among those who perceived a high risk of readmission, non-White patients (odds ratio [OR], 2.07 [95% CI, 1.28–3.36]), those with poor self-rated health (OR, 2.30 [95% CI, 1.38–3.85]), difficulty accessing care (OR, 2.72 [95% CI, 1.24–6.00]), and prior hospitalizations in the past year (OR, 2.13 [95% CI, 1.21–3.74]) were more likely to be readmitted. Among those who perceived a low risk of readmission, patients who were widowed (OR, 2.69 [95% CI, 1.60–4.51]) and reported difficulty accessing care (OR, 1.89 [95% CI, 1.07–3.33]) were more likely to be readmitted. Conclusions: Patients who perceived a high risk of readmission had a higher rate of 30-day readmission than patients who perceived a low risk. These findings have important implications for identifying CVD patients at a high risk of 30-day readmission and targeting the factors associated with perceived and actual risks of readmission.

scholarly journals Adult low-risk drinkers and abstainers are not the same

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Janette Mugavin ◽  
Sarah MacLean ◽  
Robin Room ◽  
Sarah Callinan
Keyword(s):  
Survey Research ◽  
Household Survey ◽  
Low Risk ◽  
Average Volume ◽  
Demographic Profile ◽  
Risk Levels ◽  
The Past ◽  
National Drug ◽  
Significant Difference ◽  
Low Levels

Abstract Background Alcohol consumption, even at low-levels, can not be guaranteed as safe or risk free. Specifically, the 2009 Australian National Health and Medical Research Council drinking guidelines recommend that adults should not drink more than two standard drinks on any day on average, and no more than four drinks on a single occasion. Nearly 40% of Australians aged 12 years and older drink alcohol but don’t exceed these recommended limits, yet adult low-risk drinkers have been largely overlooked in Australian alcohol survey research, where they are usually grouped with abstainers. This paper examines the socio-demographic profile of low-risk drinking adults (18+ years old), compared to those who abstain. Methods Data from the 2013 National Drug Strategy Household Survey were used. In the past 12 months, 4796 Australians had not consumed alcohol and 8734 had consumed alcohol at low-risk levels, accounting for both average volume and episodic drinking (hereafter low-risk). Results Multivariate logistic regression results indicated that low-risk drinkers were more likely to be older, married, Australian-born, and reside in a less disadvantaged neighbourhood compared with abstainers. There was no significant difference by sex between low-risk drinkers and abstainers. Conclusions The socio-demographic profile of low-risk drinkers differed from that of abstainers. Combining low-risk drinkers and abstainers into a single group, which is often the practice in survey research, may mask important differences. The study may support improved targeting of health promotion initiatives that encourage low-risk drinkers not to increase consumption or, in view of increasing evidence that low-risk drinking is not risk free, to move towards abstinence.

Successful radiofrequency ablation in an infant with drug-resistant permanent junctional reciprocating tachycardia

1999 ◽  
Vol 9 (6) ◽  
pp. 621-623 ◽  
Author(s):  
Edgar Jaeggi ◽  
Kai-Chiu Lau ◽  
Stephen G. Cooper
Keyword(s):  
Radiofrequency Ablation ◽  
Cardiac Arrhythmias ◽  
Adverse Outcome ◽  
Low Risk ◽  
Long Term Results ◽  
Drug Resistant ◽  
The Past ◽  
Neonates And Infants

AbstractOver the past decade, the technique of radiofrequency ablation has evolved substantially. Currently, most forms of cardiac arrhythmias seen in children can be treated with good long-term results and low risk of adverse outcome. Curative arrhythmia treatment with this technique, however, is still uncommon in neonates and infants. Reported here is our experience in the management of an 8-week-old with drug-resistant permanent junctional reciprocating tachycardia.

Sign in / Sign up

Export Citation Format

Share Document